Skip to content Skip to navigation



Nanobiotix, pioneer and leader in nanomedicine has developed a revolutionary concept dedicated to the local treatment of cancer. Nanobiotix is focused on the development of NanoXray, a pipeline of patented products, which are based on a physical mechanism of action: nanoparticles interact with X-rays and maximize the effect of radiotherapy within tumor cells. NanoXray products enhance the radiotherapy efficacy in the tumor without increasing healthy tissues damages. NanoXray products are built on the existing standard of care and can be used with every existing radiation equipment available in almost every hospital world-wide.

Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo and was incorporated in 2003. Nanobiotix has been primarily funded by leading European venture capital firms (Matignon Investissement et Gestion, OTC Asset Management, Cap Décisif Management, Amorçage Rhône-Alpes, CM-CIC Capital Innovation and Seventure Partners). The company has more than 30 employees and is based in Paris, France.

Nanobiotix‘s objective is to enhance its leading position in the nanomedicine field and to develop a meaningful and effective cancer treatment. With the NanoXray products the major cancers indications can be targeted (breast cancer, prostate cancer, lung cancer…) showing its huge market potential. Thanks to the physical based mechanism of action of its nanoparticles, Nanobiotix operates a unique business model with much lower risk than classic drug development, enabling a faster and less expensive time to market.

60 rue de Wattignies
Bat B
Paris, 75012
view on map
+ 33 (0) 1 40 26 04